Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-alpha-synuclein monoclonal antibody
- Development stage
- Unknown
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
Anti-alpha-synuclein monoclonal antibodies are a class of target-specific immunotherapies designed to bind to alpha-synuclein (α-syn), a presynaptic neuronal protein that misfolds and aggregates into toxic fibrils (forming Lewy bodies) in synucleinopathies such as Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA). These antibodies aim to inhibit the cell-to-cell propagation of pathological alpha-synuclein, reduce neurotoxicity, and promote clearance of aggregates by microglia. Prominent clinical-stage candidates in this class include prasinezumab (developed by Prothena and Roche) and amlenetug (Lu AF82422, developed by Lundbeck).
- Other names
- anti-aSyn antibodyanti-aSyn mAbanti-alpha-synuclein mAbanti-alpha-synuclein monoclonal antibodiesanti-α-synuclein antibodyanti-α-synuclein monoclonal antibody
02
Targets
FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)SNCA (Alpha-synuclein)Neuraminidase
Beyond the preview
Go deeper on anti-alpha-synuclein monoclonal antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-alpha-synuclein monoclonal antibody.